{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:29:27Z","timestamp":1740130167987,"version":"3.37.3"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA040499"],"award-info":[{"award-number":["R01 DA040499"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCATS Colorado CTSA","award":["UL1 TR002535"],"award-info":[{"award-number":["UL1 TR002535"]}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sofosbuvir is converted to its active form, 007 triphosphate (007-TP), within cells. To date, the association between treatment adherence and 007-TP in dried blood spots (DBS) and factors that influence this relationship remain unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To examine relationships between adherence and 007-TP concentrations in DBS and identify factors that influence 007-TP in DBS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Persons with HCV or HIV\/HCV coinfection and self-reported drug and\/or alcohol use were randomized to one of two technology-based approaches for monitoring 12\u2005week adherence to once-daily ledipasvir\/sofosbuvir. Convenience blood samples were collected every 2\u2005weeks during treatment. 007-TP in DBS was quantified using LC\/MS and analysed using mixed-effects models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 337 observations were available from 58 participants (78% male; 21% black; 22% Hispanic\/Latino; 26% cirrhotic; 78% HIV-coinfected). The mean half-life of 007-TP in DBS was 142\u2005h (95% CI 127\u2013156) and concentrations increased by 7.3% (95% CI 2.2\u201312.6) for every 10% increase in between-visit adherence. Geometric mean (95% CI) 007-TP concentrations in DBS were 301 (247\u2013368), 544 (462\u2013639) and 647 (571\u2013723)\u2005fmol\/punch by adherence categories of \u226450%, &amp;gt;50 to \u226480%, and &amp;gt;80%. Adherence, time on therapy, increasing age and decreased estimated glomerular filtration rate were associated with higher 007-TP, whereas increased time since last dose, male sex, black race and higher BMI were associated with lower 007-TP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>007-TP has an extended half-life in DBS and concentrations increased with adherence. Further research is needed to examine additional factors that affect 007-TP and the clinical utility of this measure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac051","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T12:12:01Z","timestamp":1644581521000},"page":"1396-1403","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-8699","authenticated-orcid":false,"given":"Kristina M","family":"Brooks","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose R","family":"Castillo-Mancilla","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Morrow","sequence":"additional","affiliation":[{"name":"Colorado School of Public Health, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Mawhinney","sequence":"additional","affiliation":[{"name":"Colorado School of Public Health, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E","family":"Rowan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"},{"name":"Denver Health and Hospital Authority , Denver, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wyles","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"},{"name":"Denver Health and Hospital Authority , Denver, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Blum","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority , Denver, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Huntley","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Salah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arya","family":"Tehrani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah C","family":"Jimmerson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Roon","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lane R","family":"Bushman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J","family":"Kiser","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"2022110403483374600_dkac051-B1","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"2022110403483374600_dkac051-B2","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"2022110403483374600_dkac051-B3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"2022110403483374600_dkac051-B4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022110403483374600_dkac051-B5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada","volume":"47","author":"Mason","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2022110403483374600_dkac051-B6","doi-asserted-by":"crossref","first-page":"ofz166","DOI":"10.1093\/ofid\/ofz166","article-title":"A randomized controlled trial of cash incentives or peer support to increase HCV treatment for persons with HIV who use drugs: the CHAMPS study","volume":"6","author":"Ward","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022110403483374600_dkac051-B7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.drugalcdep.2018.11.007","article-title":"Glecaprevir\/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies","volume":"194","author":"Foster","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2022110403483374600_dkac051-B8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022110403483374600_dkac051-B9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12072-015-9680-7","article-title":"High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study","volume":"10","author":"Petersen","year":"2016","journal-title":"Hepatol Int"},{"key":"2022110403483374600_dkac051-B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"author":"Litwin","key":"2022110403483374600_dkac051-B11","article-title":"High rates of sustained virologic response in people who inject drugs treated with all-oral direct acting antiviral regimens"},{"key":"2022110403483374600_dkac051-B12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann Intern Med"},{"key":"2022110403483374600_dkac051-B13","doi-asserted-by":"crossref","first-page":"ofaa564","DOI":"10.1093\/ofid\/ofaa564","article-title":"Adherence to direct-acting antiviral therapy in people actively using drugs and alcohol: the INCLUD study","volume":"8","author":"Brooks","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2022110403483374600_dkac051-B14","doi-asserted-by":"crossref","first-page":"e15532","DOI":"10.2196\/15532","article-title":"Wirelessly observed therapy to optimize adherence and target interventions for oral hepatitis C treatment: observational pilot study","volume":"22","author":"Bonacini","year":"2020","journal-title":"J Med Internet Res"},{"key":"2022110403483374600_dkac051-B15","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/apt.15707","article-title":"Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence","volume":"51","author":"Sulkowski","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"author":"Leo","key":"2022110403483374600_dkac051-B16","article-title":"Impact of a smartphone-based artificial intelligence platform on hepatitis C adherence in a real-world population"},{"key":"2022110403483374600_dkac051-B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000002354","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS study","volume":"84","author":"Yager","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022110403483374600_dkac051-B18","doi-asserted-by":"crossref","first-page":"e01710-17","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"Anderson","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403483374600_dkac051-B19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/aid.2014.0229","article-title":"Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women","volume":"31","author":"Castillo-Mancilla","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022110403483374600_dkac051-B20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure","volume":"29","author":"Castillo-Mancilla","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022110403483374600_dkac051-B21","doi-asserted-by":"crossref","first-page":"e1893","DOI":"10.1093\/cid\/ciaa1872","article-title":"Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa","volume":"73","author":"Stranix-Chibanda","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022110403483374600_dkac051-B22","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/QAD.0000000000001922","article-title":"Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis","volume":"32","author":"Pyra","year":"2018","journal-title":"AIDS"},{"key":"2022110403483374600_dkac051-B23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/cid\/ciy708","article-title":"Tenofovir diphosphate in dried blood spots is strongly associated with viral suppression in individuals with human immunodeficiency virus infections","volume":"68","author":"Castillo-Mancilla","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022110403483374600_dkac051-B24","doi-asserted-by":"crossref","first-page":"151ra25","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"2022110403483374600_dkac051-B25","doi-asserted-by":"crossref","first-page":"ofaa577","DOI":"10.1093\/ofid\/ofaa577","article-title":"Associations between tenofovir diphosphate in dried blood spots, impaired physical function, and fracture risk","volume":"8","author":"Abdo","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022110403483374600_dkac051-B26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/jac\/dkaa070","article-title":"Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV","volume":"75","author":"Coyle","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022110403483374600_dkac051-B27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jiz144","article-title":"Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV","volume":"220","author":"Morrow","year":"2019","journal-title":"J Infect Dis"},{"key":"2022110403483374600_dkac051-B28","doi-asserted-by":"crossref","first-page":"2325958219888457","DOI":"10.1177\/2325958219888457","article-title":"Moderately high tenofovir diphosphate in dried blood spots indicates drug resistance in viremic persons living with HIV","volume":"18","author":"Yager","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2022110403483374600_dkac051-B29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/QAI.0000000000002247","article-title":"Antenatal intracellular concentrations of tenofovir diphosphate and emtricitabine triphosphate and associations between tenofovir diphosphate and severe adverse pregnancy outcomes: IMPAACT-PROMISE (1077BF) trial","volume":"83","author":"Aizire","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022110403483374600_dkac051-B30","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1097\/QAD.0000000000002981","article-title":"Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence","volume":"35","author":"Morrow","year":"2021","journal-title":"AIDS"},{"author":"AASLD\/IDSA\/IAS-USA","key":"2022110403483374600_dkac051-B31","article-title":"HCV guidance: recommendations for testing, managing, and treating hepatitis C"},{"key":"2022110403483374600_dkac051-B32","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jphp.12294","article-title":"Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus","volume":"66","author":"Summers","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"2022110403483374600_dkac051-B33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","article-title":"Sofosbuvir, a significant paradigm change in HCV treatment","volume":"3","author":"McQuaid","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"2022110403483374600_dkac051-B34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2022110403483374600_dkac051-B35","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1128\/AAC.01693-15","article-title":"Validation and application of a liquid chromatography-tandem mass spectrometry method to determine the concentrations of sofosbuvir anabolites in cells","volume":"59","author":"Rower","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403483374600_dkac051-B36","first-page":"4","article-title":"Intracellular 007-TP concentrations are associated with gradients of adherence to ledipasvir\/sofosbuvir","volume":"4","author":"Jimmerson","year":"2018","journal-title":"Rev Antivir Ther Infect Dis"},{"key":"2022110403483374600_dkac051-B37","first-page":"35","article-title":"Plasma pharmacokinetics of sofosbuvir and 007 in persons with HCV and active drug use","volume":"4","author":"Brooks","year":"2019","journal-title":"Rev Antivir Ther Infect Dis"},{"key":"2022110403483374600_dkac051-B38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of \u03b2-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine involves a second metabolic pathway leading to \u03b2-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine 5\u2032-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403483374600_dkac051-B39","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"key":"2022110403483374600_dkac051-B40","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/aid.2016.0008","article-title":"Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state","volume":"32","author":"Seifert","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"author":"CDC","key":"2022110403483374600_dkac051-B41","article-title":"Alcohol and Public Health: Alcohol Basics"},{"year":"2020","author":"Harvoni (package insert). Gilead Sciences, Inc.","key":"2022110403483374600_dkac051-B42"},{"key":"2022110403483374600_dkac051-B43","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/2041-210X.12225","article-title":"Extension of Nakagawa & Schielzeth\u2019s R-GLMM(2) to random slopes models","volume":"5","author":"Johnson","year":"2014","journal-title":"Methods Ecol Evol"},{"key":"2022110403483374600_dkac051-B44","doi-asserted-by":"crossref","first-page":"20170213","DOI":"10.1098\/rsif.2017.0213","article-title":"The coefficient of determination R2 and intra-class correlation coefficient from generalized linear mixed-effects models revisited and expanded","volume":"14","author":"Nakagawa","year":"2017","journal-title":"J R Soc Interface"},{"key":"2022110403483374600_dkac051-B45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.2041-210x.2012.00261.x","article-title":"A general and simple method for obtaining R2 from generalized linear mixed-effects models","volume":"4","author":"Nakagawa","year":"2013","journal-title":"Methods Ecol Evol"},{"key":"2022110403483374600_dkac051-B46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/00031305.2016.1256839","article-title":"A coefficient of determination for generalized linear models","volume":"71","author":"Zhang","year":"2017","journal-title":"Am Stat"},{"key":"2022110403483374600_dkac051-B47","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/jac\/dky146","article-title":"Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV\/HCV-coinfected individuals receiving tenofovir disoproxil fumarate","volume":"73","author":"MacBrayne","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022110403483374600_dkac051-B48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/aid.2020.0108","article-title":"Individualized adherence benchmarks for HIV pre-exposure prophylaxis","volume":"37","author":"Ibrahim","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"author":"Center for Drug Evaluation and Research, U.S. FDA","key":"2022110403483374600_dkac051-B49","article-title":"Clinical Pharmacology and Biopharmaceutics Review of Sofosbuvir\/Ledipasvir"},{"author":"Jin","key":"2022110403483374600_dkac051-B50","article-title":"Population pharmacokinetic modeling of sofosbuvir, an NS5b polymerase inhibitor, and its metabolites in patients with Hepatitis C virus infection"},{"author":"Center for Drug Evaluation and Research, U.S. FDA","key":"2022110403483374600_dkac051-B51","article-title":"Clinical Pharmacology and Biopharmaceutics Review of Sofosbuvir\/Velpatasvir"},{"author":"Center for Drug Evaluation and Research, U.S. FDA","key":"2022110403483374600_dkac051-B52","article-title":"Clinical Pharmacology and Biopharmaceutics Review of Sofosbuvir\/Velpatasvir\/Voxilaprevir"},{"key":"2022110403483374600_dkac051-B53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/ciy201","article-title":"Drug-drug interaction studies between hepatitis C virus antivirals sofosbuvir\/velpatasvir and boosted and unboosted human immunodeficiency virus antiretroviral regimens in healthy volunteers","volume":"67","author":"Mogalian","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022110403483374600_dkac051-B54","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1128\/AAC.01263-12","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection","volume":"57","author":"Lawitz","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403483374600_dkac051-B55","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/jac\/dkz184","article-title":"Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir\/sofosbuvir","volume":"74","author":"Brooks","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022110403483374600_dkac051-B56","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2016.11.025","article-title":"Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil","volume":"66","author":"Shen","year":"2017","journal-title":"J Hepatol"},{"key":"2022110403483374600_dkac051-B57","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/jac\/dkz187","article-title":"Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate","volume":"74","author":"Brooks","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022110403483374600_dkac051-B58","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/jac\/dkaa299","article-title":"Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir\/sofosbuvir","volume":"75","author":"Brooks","year":"2020","journal-title":"J Antimicrob Chemother"},{"author":"Garrison","key":"2022110403483374600_dkac051-B59","article-title":"Drug interactions between anti-HCV antivirals ledipasvir\/sofosbuvir and integrase strand transfer inhibitor-based regimens"},{"issue":"Suppl","key":"2022110403483374600_dkac051-B60","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.dmpk.2017.11.182","article-title":"Inhibition of carboxylesterase 2 (CES2) by sofosbuvir: metabolism-reduced potency, in vivo inhibition and reduced activation of the anti-HIV drug tenofovir disoproxil","volume":"33","author":"Shen","year":"2018","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1396\/46783343\/dkac051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1396\/46783343\/dkac051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T03:49:45Z","timestamp":1667533785000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/5\/1396\/6534629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,2,23]]},"published-print":{"date-parts":[[2022,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac051","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,2,23]]}}}